India Mounjaro Market Size, Share, Growth, and Industry Analysis, By Indication (Type 2 Diabetes, Obesity/Weight Management, Prediabetes/Metabolic Syndrome, Others), By Route of Administration (Injectable, Oral) and Forecast, 2026-2034

India Mounjaro Market Trends

Rapid Shift Toward Convenient Weekly Metabolic Therapy

Once-weekly administration is reshaping metabolic-drug utilization as patients and physicians increasingly evaluate therapies combining glycemic control and weight management. Lilly expanded the Indian delivery platform in August 2025 with the KwikPen across 6 dosage strengths ranging from 2.5 mg to 15 mg. Monthly KwikPen pricing started at INR 14,000 for 2.5 mg and reached INR 27,500 for the 12.5 mg and 15 mg strengths, reinforcing a shift toward convenient self-administration.

Early commercial adoption has been substantial despite premium pricing. Mounjaro generated approximately INR 233 crore in Indian sales during its first 6 months and recorded around INR 80 crore in September 2025 alone, making it the country’s second-highest-selling pharmaceutical brand by monthly value at that point. Earlier, May 2025 sales had increased approximately 60% from April, demonstrating rapid uptake among diabetes and obesity patients.

India Mounjaro Market Drivers

Large Diabetes and Obesity Treatment Pool Accelerates Prescription Uptake

India’s expanding metabolic-disease treatment requirement is the principal commercial driver. Mounjaro combines GIP and GLP-1 receptor activity and is administered once weekly, supporting physician interest in therapies addressing both glycemic and weight outcomes. Initial Indian pricing ranged from INR 3,500 to INR 4,375 per vial, equivalent to approximately INR 14,000–17,500 for 4 weekly doses at introductory strengths. Commercial traction was visible when sales increased roughly 60% month-over-month in May 2025 and subsequently reached INR 80 crore in September, highlighting substantial demand despite out-of-pocket treatment costs.

India Mounjaro Market Restraints

Premium Therapy Costs Restrict Broad-Based Patient Accessibility

Affordability remains a significant constraint because chronic treatment requires repeated weekly dosing. Initial monthly expenditure was approximately INR 14,000–17,500, while KwikPen pricing later ranged from INR 14,000 for 2.5 mg to INR 27,500 for 12.5 mg and 15 mg doses. This represents nearly a 96% difference between the lowest and highest monthly KwikPen price points. Such expenditure can constrain penetration among self-paying patients and increase sensitivity to lower-priced GLP-1 alternatives.

India Mounjaro Market Opportunities

Expansion Across Dose Strengths and Digital Pharmacy Access Broadens Addressable Patients

Commercial opportunity is widening through formulation convenience, dose personalization and pharmacy access. The KwikPen portfolio spans 6 strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg—supporting progressive dose escalation under medical supervision. Prices range from INR 14,000 to INR 27,500 depending on strength. The combination of weekly dosing, multi-strength availability and growing digital-pharmacy infrastructure can improve continuity for metropolitan patients while supporting expansion beyond the initial vial-based launch.

Challenges in India Mounjaro Market

Competitive GLP-1 Pricing and Long-Term Treatment Persistence Intensify Commercial Pressure

The principal challenge is sustaining treatment persistence as competing GLP-1 therapies expand. Mounjaro’s monthly KwikPen expenditure can reach INR 27,500 at 12.5–15 mg versus INR 14,000 at 2.5 mg, while therapy requires 4 weekly administrations per month. At the same time, early sales reached INR 233 crore within 6 months, demonstrating demand but also attracting intensified competitive attention. Maintaining supply, physician confidence and patient adherence will therefore remain critical as India’s incretin-therapy landscape becomes more price competitive.

India Mounjaro Market Segmentation

The market is segmented by indication, route of administration, dosage strength and distribution channel. Based on supplied 2026 data, type 2 diabetes holds 40.67% of indication value, followed by obesity/weight management at 33.71%, prediabetes/metabolic syndrome at 15.71%, and others at 9.91%. By route, injectable products account for 56.31%, compared with 43.69% for oral administration.

By Indication

Type 2 diabetes is the largest indication, increasing from USD 322.50 million in 2025 to USD 380.07 million in 2026 and USD 1,414.15 million by 2034 at a 17.85% CAGR. Its 40.67% contribution in 2026 reflects the core therapeutic positioning of tirzepatide within glycemic management.

Prediabetes/metabolic syndrome is the fastest-growing supplied indication at a 21.67% CAGR, reaching USD 705.22 million by 2034 from USD 146.84 million in 2026. Obesity/weight management also expands strongly at 20.97%, from USD 314.99 million to USD 1,444.52 million, while other indications register a 17.79% CAGR.

By Route of Administration

Injectable administration leads the route category with USD 527.22 million in 2026, equivalent to 56.31% of the supplied route-based total. Revenue is projected to reach USD 2,365.50 million by 2034, representing a 20.64% CAGR and making injectables both the largest and fastest-growing supplied route.

Oral administration accounts for USD 409.04 million in 2026 and is forecast to reach USD 1,590.42 million by 2034 at an 18.50% CAGR. The supplied route table reports an overall 2026 total of USD 936.26 million and a 2034 total of USD 3,955.92 million.

By Dosage Strength

The dosage-strength segmentation comprises 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, representing 6 titration levels. Public launch information confirms monthly KwikPen prices of INR 14,000 for 2.5 mg, INR 17,500 for 5 mg, INR 22,000 for 7.5 mg and 10 mg, and INR 27,500 for 12.5 mg and 15 mg.

No revenue or CAGR split by dosage strength was supplied; therefore, no unsupported segment valuation is assigned. The 6-strength architecture nevertheless provides a 2.5–15 mg dosing range, allowing treatment escalation while maintaining once-weekly administration.

By Distribution Channel

Distribution comprises retail pharmacies, hospital pharmacies, online pharmacies and specialty pharmacies, representing 4 principal channels. The overall indication-based value reaches USD 934.49 million in 2026, while channel-specific revenue shares and CAGRs were not supplied and are therefore not estimated.

Retail and hospital pharmacies support prescription initiation and continuity, while online and specialty channels can strengthen refill accessibility. Early national commercial performance of INR 233 crore within 6 months of launch illustrates the scale of pharmacy-channel demand developing around tirzepatide.

India Mounjaro Market Outlook

India constitutes 100% of the geographic scope covered by this report. The supplied indication-based national value rises from USD 782.19 million in 2025 to USD 934.49 million in 2026 and USD 3,907.02 million in 2034. Type 2 diabetes contributes 40.67% of 2026 indication revenue and obesity/weight management contributes 33.71%, together representing 74.38% of the national indication mix.

State-, city- and zone-level revenue shares or production volumes were not supplied; consequently, North, South, East, West and Central India percentages are not fabricated. Nationally, injectable administration represents 56.31% of the separate route-based 2026 total, while oral administration represents 43.69%. Commercial evidence shows INR 80 crore of sales in September 2025 and INR 233 crore cumulatively during the first 6 months after launch.

Top players in India Mounjaro Market

1. Eli Lilly and Company
2. Novo Nordisk A/S
3. Cipla Limited
4. Sun Pharmaceutical Industries Ltd.
5. Dr. Reddy’s Laboratories Ltd.
6. Biocon Limited
7. Lupin Limited
8. Zydus Lifesciences Limited
9. Glenmark Pharmaceuticals Limited
10. Torrent Pharmaceuticals Limited
11. Alkem Laboratories Limited
12. Mankind Pharma Limited

Top Two Companies

• Eli Lilly and Company:Mounjaro is Lilly’s proprietary tirzepatide brand, making Lilly responsible for 100% of branded Mounjaro commercialization considered in this narrowly defined product market rather than a multi-manufacturer share structure. The company launched the product in India in March 2025 with 2.5 mg and 5 mg vials priced at INR 3,500 and INR 4,375 respectively. It subsequently introduced 6 KwikPen strengths from 2.5 mg through 15 mg. Sales reached approximately INR 233 crore within the first 6 months, including INR 80 crore during September 2025, establishing a strong first-mover position in India’s tirzepatide category.
• Novo Nordisk A/S:Novo Nordisk does not sell Mounjaro and therefore has 0% share of the branded Mounjaro product itself; its relevance is as a major competing incretin-therapy company through semaglutide products. Competitive positioning is important because India’s diabetes and obesity market increasingly compares dual GIP/GLP-1 tirzepatide with GLP-1-based alternatives on efficacy, convenience and price. Lilly’s rapid INR 233 crore first-6-month performance intensified this competitive environment, while the broader category continues moving toward weekly injectable and increasingly convenient treatment formats.

Recent Developments in India Mounjaro Market

• 2026: Lilly's global Mounjaro revenue reached approximately USD 9.94 billion in Q2 2026, up 91%, reflecting continued international momentum for tirzepatide.
• 2025: Eli Lilly launched Mounjaro in India in March at INR 3,500 for 2.5 mg and INR 4,375 for 5 mg single-dose vials.
• 2025: Mounjaro sales in India increased approximately 60% in May compared with April during its early commercialization period.
• 2025: Lilly introduced the Mounjaro KwikPen in India with 6 strengths from 2.5 mg to 15 mg and monthly pricing between INR 14,000 and INR 27,500.
• 2025: Mounjaro accumulated approximately INR 233 crore in Indian sales within 6 months and recorded INR 80 crore during September, ranking second among pharmaceutical brands by monthly sales at that time.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied tables form the primary quantitative basis for market valuation, segment contribution and CAGR calculations. Indication-based values of USD 782.19 million in 2025, USD 934.49 million in 2026 and USD 3,907.02 million in 2034 are retained without alteration. The separate route table reports USD 782.20 million, USD 936.26 million and USD 3,955.92 million respectively; these figures are presented independently rather than reconciled through unsupported assumptions. Secondary evidence is used only for launch timing, pricing, sales traction, product format and competitive context.